The prognostic heterogeneity of the World Health Organization category of 'Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD)' has not been systematically validated by primary data. Among 138 consecutive cases with SM-AHNMD, 123 (89%) had associated myeloid neoplasm: 55 (45%) myeloproliferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia (SM-CMML), 28 (23%) myelodysplastic syndrome (SM-MDS), and 4 (3%) acute leukemia (SM-AL). Of the myeloid subgroups, SM-MPN displayed a 2-3-fold better life expectancy (p=0.003) whereas leukemic transformation was more frequent in SM-MDS (29%; p=0.02). Presence of eosinophilia, although prevalent (34%), was prognostically neutral, and the overall results were not affected by exclusion of FIP1L1-
Introduction
The 2008 World Health Organization (WHO) classification of systemic mastocytosis (SM) recognizes 4 major disease variants: (i) indolent SM (ISM), (ii) SM with associated clonal hematological non-mast cell lineage disease (SM-AHNMD), (iii) aggressive SM (ASM), and (iv) mast cell leukemia (MCL). 1 In their study of 66 SM patients, Travis et al. found SM-AHNMD to be the second most common subtype (after ISM), with 22 patients (33%). 2 Eighteen patients (82%) had an associated clonal myeloid malignancy, with myelodysplastic syndrome (MDS) being observed most frequently (32%). In this series, the 5-year survival of SM-AHNMD patients was 28% as compared to 61% for other SM patients. Horny and colleagues similarly found SM-AHNMD to be the second most common subtype (n=20)
in their series of 64 SM patients. 3 Eighteen patients (90%) had an associated myeloid neoplasm, with chronic myelomonocytic leukemia (CMML) representing the most frequent entity (39%). As in the series by Travis et al., the SM component was discovered incidentally in most cases, during evaluation of the associated hematological disorder.
While the pathophysiologic relationship between the 'SM' and 'AHNMD' components in SM-AHNMD patients remains to be precisely delineated, lineage distribution studies of the KITD816V mutation suggests that a common pluripotent hematopoietic stem cell is targeted in most patients. [4] [5] [6] In some cases, however, the 2 clonal hematological disorders may develop coincidentally.
7
The current WHO category of SM-AHNMD does not clarify the prognostic impact of specific molecular and cytogenetic abnormalities, presence of eosinophilia, and specific therapies upon life expectancy and risk of leukemic transformation within the 
Materials and Methods
The current study was approved by the Mayo Clinic institutional review board.
The study population was drawn from a previously reported larger study of 342 adult SM Actuarial probability of survival was estimated using the Kaplan-Meier product limit method. Comparison between Kaplan-Meier curves were carried out by the log- Statistical analyses of the data were carried out using the StatView software package (SAS version 9.1, Institute Inc, Cary, NC).
Results and Discussion
Among 342 consecutive adult patients with SM, 138 (40%) had SM-AHNMD. In contrast to previous reports, we observed a high prevalence of prominent eosinophilia (≥ 1.5 x 10 9 /L) at presentation (n= 42; 34%), most commonly in the SM-MPN category (56%; p<0.0001) (Table) . Of the latter, 48% (n=15) could be classified as SM-CEL (12 harbored FIP1L1-PDGFRA, 2 other clonal cytogenetic abnormalities, and 1 BM blasts >5%). Clinical outcome was similar between SM-MPN patients with or without eosinophilia. However, SM-MPN patients with eosinophilia were more likely to be males (87% vs. 58%; p=0.03) and exhibit a 'loose' pattern of MC infiltration in BM trephines (54% versus 5%; p=0.0005) (Supplemental Figure) .
Results of cytogenetic and molecular testing are presented in the Table ( individual cytogenetic abnormalities are listed in Supplemental Table 2 ). Abnormal karyotype was most frequent in SM-AL (100%; n=4), however its distribution amongst the other subgroups was similar. KITD816V mutational frequency was similar among the different subgroups, and JAK2V617F occurrence was limited to SM-MPN. The frequency of abnormal karyotype in patients with prominent eosinophilia was 24%. Twenty six SM patients with prominent eosinophilia underwent molecular testing for KITD816V and JAK2V617F; the respective mutational frequencies were 50% and 8%. Nineteen patients with prominent eosinophilia were evaluated for FIP1L1-PDGFRA and 12 (63%) harbored the mutation; 8 of these 12 FIP1L1-PDGFRA-positve cases were also screened for KITD816V and JAK2V617F and all tested negative. Leukemic transformation (n=16; 13% overall) was observed significantly more frequently in SM-MDS (29%), as compared to SM-MPN (11%) or SM-CMML (6%) (p=0.02).
A summary of SM patients with associated myeloid neoplasia who received at least one cytoreductive therapy is provided in Supplemental Table 3 . In general, FIP1L1-PDGFRA-positive disease almost always responds to treatment with imatinib mesylate.
Response is infrequent in the absence of this molecular marker. Approximately 50% of treated subjects responded to interferon-alpha or 2-chlorodeoxyadenosine. Response to hydroxyurea therapy was infrequent and modest.
We recently reported on the prognostic relevance of the WHO proposed classification for SM. 8 In the current paper, we point out the limited clinical usefulness of the term 'SM-AHNMD' and provide evidence to support its substitution by a prognostically more useful sub-categorization that includes 'SM-MPN', 'SM-CMML', 'SM-MDS' and 'SM-AL'. Finally, we demonstrate that FIP1L1-PDGFRA-negative eosinophilia is prevalent in SM associated with a myeloid malignancy but does not modify prognosis within a specific subcategory.
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Laboratory findings
Hemoglobin (g/dL) 123 (100) 10.6 (6.4-17.4) 11.8 (6.6-17.4) 10.6 (7.7-15.4) 9.5 (6.4-13.3) 10.3 (7.5-13.4) 
